Page
%P
-
Article
Open AccessStructure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies
Hepatitis C virus (HCV) is a major global health burden as the leading causative agent of chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV-neutralizing antibodies is ...
-
Protocol
Low-Cost Peptide Microarrays for Map** Continuous Antibody Epitopes
Understanding antibody specificity and defining response profiles to antigens continue to be essential to both vaccine research and therapeutic antibody development. Peptide scanning assays enable map** of c...
-
Article
Open AccessA structured RNA motif locks Argonaute2:miR-122 onto the 5’ end of the HCV genome
microRNAs (miRNAs) form regulatory networks in metazoans. Viruses engage miRNA networks in numerous ways, with Flaviviridae members exploiting direct interactions of their RNA genomes with host miRNAs. For hepati...
-
Article
Author Correction: Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy
Protein-based therapeutics can activate the adaptive immune system, leading to the production of neutralizing antibodies and the clearance of the treated cells mediated by cytotoxic T cells. Here, we show that...
-
Book
-
Protocol
Probing the Antigenicity of HCV Envelope Glycoproteins by Phage Display Antibody Technology
The envelope glycoproteins E1 and E2 of hepatitis C virus form a heterodimeric complex on the viral surface. They are the targets of neutralizing antibodies and are being investigated as potential vaccine anti...
-
Protocol
Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp)
Hepatitis C virus (HCV) pseudoparticles (HCVpp) are generated by cotransfection of HCV envelope (E1 and E2) genes along with a retroviral packaging/reporter construct into HEK293T cells. Enveloped particles be...
-
Protocol
Detection of Antibodies to HCV E1E2 by Lectin-Capture ELISA
Enzyme-linked immunosorbent assays (ELISAs) enable rapid detection and quantitation of antibodies in samples. Such assays can be highly sensitive and can be performed in most laboratories with basic equipment....
-
Protocol
Simultaneous Quantification of Hepatitis C Virus Envelope Glycoproteins E1 and E2 by Dual-Color Fluorescence Immunoblot Analysis
The hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, are crucial for HCV assembly and entry, and are promising vaccine antigens. However, they are challenging to study because of technical difficulti...
-
Protocol
Low-Cost Peptide Microarrays for Map** Continuous Antibody Epitopes
With the increasing need for understanding antibody specificity in antibody and vaccine research, pepscan assays provide a rapid method for map** and profiling antibody responses to continuous epitopes. We h...
-
Article
Open AccessApproaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding
Development of a prophylactic vaccine against hepatitis C virus (HCV) has been hampered by the extraordinary viral diversity and the poor host immune response. Scaffolding, by grafting an epitope onto a hetero...
-
Article
Completion of the entire hepatitis C virus life cycle in genetically humanized mice
The entire hepatitis C virus life cycle can be recapitulated in an inbred mouse model, allowing preclinical assessment of antiviral therapeutics and vaccines.
-
Article
A genetically humanized mouse model for hepatitis C virus infection
The development of therapies for hepatitis C virus (HCV) infection has been hampered by the lack of a small-animal model of the disease. Now Alexander Ploss and colleagues describe the first immunocompetent ro...
-
Article
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge
A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isol...
-
Article
Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination
Smallpox was eradicated without an adequate understanding of how vaccination induced protection. In response to possible bioterrorism with smallpox, the UK government vaccinated ∼300 health care workers with v...
-
Protocol
Studying the Binding and Entry of the Intracellular and Extracellular Enveloped Forms of Vaccinia Virus
This chapter describes the methods for the study of binding and entry of the two different forms of vaccinia virus (VV)—the intracellular mature virus (IMV) and extracellular enveloped virus (EEV)—using immuno...
